12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Heplisav: Phase III ongoing

Dynavax said an independent DSMB recommended continuation of a pair of Phase III trials of Heplisav after reviewing safety data from patients. In September 2009, the company said FDA lifted a clinical hold that was...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >